Olio Labs, a San Francisco, CA-based provider of a therapeutic design platform, raised $4.5M in funding.
The round was led by Boom Capital and Overwater Ventures, with participation from Pioneer Fund, SciFounders, Scrum Ventures, Y Combinator (S23), and ZAKA.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO David Tingley, Olio Labs has developed a therapeutic design platform that moves beyond traditional drug discovery methods. Its AI-powered combination design engine (CoDE) platform leverages:
- uman medical record and biological data
- In-vivo phenomic screening
- In-depth neural and endocrine circuit maps
- AI-powered integration of biological expertise
The company’s advisory board includes industry veterans like Patricia Martin (former COO of Eli Lilly Diabetes), Michael Schwartz (Professor of Medicine, University of Washington), and Hugh Reinhoff (Founder & CEO of Imago BioSciences).
FinSMEs
20/03/2025